Drug Trial Radar · NCT01959139
S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Feb 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
126
Actual
Start
Jan 23, 2014
Primary completion
Apr 2019
Study completion Nov 9, 2023
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); Halozyme Therapeutics
- First posted
- Oct 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This partially randomized phase I/II trial studies the side effects and best dose of pegylated recombinant human hyaluronidase (PEGPH20) when given together with combination chemotherapy and to see how well they work compared with combination chemotherapy alone in treating patients with newly diagnosed pancreatic cancer that has spread to other places in the body. Pegylated recombinant human hyaluronidase may help chemotherapy drugs work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without pegylated recombinant human hyaluronidase in treating pancreatic cancer.
Conditions
- Metastatic Pancreatic Adenocarcinoma
Interventions
PEGPH20Drug
3 ug/kg on Day 1, IV over 15 minutes
OxaliplatinDrug
85 mg/m\^2, on Day 2, IV over 2 hours
LeucovorinDrug
400 mg/m\^2, on Day 2, IV over 2 hours
IrinotecanDrug
180 mg/m\^2, on Day 2, IV over 1.5 hours
5-fluorouracilDrug
2,400 mg/m\^2, Days 2-4, IV over 46 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With mFOLFIRINOXTime frame: 2 cycles of 14 days
- Phase II: Overall SurvivalTime frame: From date of registration to date of death due to any cause, assessed up to 3 years
Locations
154 sites in 1 country. Site status is shown where the registry gives one.
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
University of Arizona Cancer Center-North Campus
Tucson, Arizona
The University of Arizona Medical Center-University Campus
Tucson, Arizona
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills - Peninsula Hospitals
Burlingame, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Eden Hospital Medical Center
Castro Valley, California
City of Hope Corona
Corona, California
UC Irvine Health Cancer Center-Newport
Costa Mesa, California
Sutter Davis Hospital
Davis, California
City of Hope Comprehensive Cancer Center
Duarte, California
Los Angeles County-USC Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Fremont - Rideout Cancer Center
Marysville, California
Memorial Medical Center
Modesto, California
Palo Alto Medical Foundation-Camino Division
Mountain View, California
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California
Sutter Cancer Research Consortium
Novato, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California
Sutter Roseville Medical Center
Roseville, California
Sutter General Hospital
Sacramento, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
California Pacific Medical Center-Pacific Campus
San Francisco, California
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California
Sutter Pacific Medical Foundation
Santa Rosa, California
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California
Gene Upshaw Memorial Tahoe Forest Cancer Center
Truckee, California
Sutter Cancer Centers Radiation Oncology Services-Vacaville
Vacaville, California
Sutter Solano Medical Center/Cancer Center
Vallejo, California
City of Hope West Covina
West Covina, California
Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.